<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Cronos Group Inc. (CRON)” data-reactid=”13″>Cronos Group Inc. (CRON)
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Investors Affected: May 9, 2019 – March 2, 2020” data-reactid=”14″>Investors Affected: May 9, 2019 – March 2, 2020
A class action has commenced on behalf of certain shareholders in Cronos Group Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Cronos had engaged in significant transactions for which its revenue recognition was inappropriate; (ii) the foregoing would foreseeably necessitate reviews that would delay the Company’s ability to timely file its periodic reports; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Shareholders may find more information at https://securitiesclasslaw.com/securities/cronos-group-inc-loss-submission-form/?id=5985&from=1” data-reactid=”16″>Shareholders may find more information at https://securitiesclasslaw.com/securities/cronos-group-inc-loss-submission-form/?id=5985&from=1
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="AnaptysBio, Inc. (ANAB)” data-reactid=”17″>AnaptysBio, Inc. (ANAB)
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Investors Affected: October 10, 2017 – November 7, 2019” data-reactid=”18″>Investors Affected: October 10, 2017 – November 7, 2019
A class action has commenced on behalf of certain shareholders in AnaptysBio, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) AnaptysBio failed to disseminate important data from the Company’s Phase 2a trial in atopic dermatitis, including the timing and extent of patients’ use of topical corticosteroids as a rescue therapy during the study and whether any of the patients that utilized rescue therapy were classified as responders at a given time;and (ii) the Company’s statements omitted key information from the Company’s Phase 2a trial in peanut allergy, including patients’ average cumulative peanut dose tolerated at day 14 after the administration of etokimab or placebo as well as whether the Company’s decision to exclude 20% of the patients enrolled in the study from the interim analysis due to their mild symptoms was retrospective; and (ii) as a result of the foregoing, Defendants’ positive statements about the efficacy and prospects of AnaptysBio’s lead drug asset in the treatment of atopic dermatitis and peanut allergy were materially false and/or misleading and/or lacked a reasonable basis.
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Shareholders may find more information at https://securitiesclasslaw.com/securities/anaptysbio-inc-loss-submission-form/?id=5985&from=1” data-reactid=”20″>Shareholders may find more information at https://securitiesclasslaw.com/securities/anaptysbio-inc-loss-submission-form/?id=5985&from=1
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Zoom Video Communications, Inc. (ZM)” data-reactid=”21″>Zoom Video Communications, Inc. (ZM)
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Investors Affected: April 18, 2019 – April 6, 2020” data-reactid=”22″>Investors Affected: April 18, 2019 – April 6, 2020
A class action has commenced on behalf of certain shareholders in Zoom Video Communications, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Zoom had inadequate data privacy and security measures; (ii) contrary to Zoom’s assertions, the Company’s video communications service was not end-to-end encrypted; (iii) as a result of all the foregoing, users of Zoom’s communications services were at an increased risk of having their personal information accessed by unauthorized parties, including Facebook; (iv) usage of the Company’s video communications services was foreseeably likely to decline when the foregoing facts came to light; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Shareholders may find more information at https://securitiesclasslaw.com/securities/zoom-video-communications-inc-loss-submission-form/?id=5985&from=1” data-reactid=”24″>Shareholders may find more information at https://securitiesclasslaw.com/securities/zoom-video-communications-inc-loss-submission-form/?id=5985&from=1
The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company’s stock. Attorney advertising. Prior results do not guarantee similar outcomes.
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (212) 537-9430
Fax: (833) 862-7770″ data-reactid=”26″>CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (212) 537-9430
Fax: (833) 862-7770
Add Comment